Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk stock rose rapidly early Friday after a study from the University of Oxford showed its diabetes and weight-loss drug, semaglutide, could lower the risk of developing dementia.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 12 trades. If we consider the specifics of ...

This collaboration unites Novo Nordisk’s deep therapeutic knowledge ... selectivity and drug-like properties. Founded through MIT and based in Cambridge, Massachusetts, Gensaic's award-winning ...